vs

Side-by-side financial comparison of NexPoint Real Estate Finance, Inc. (NREF) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.1M, roughly 1.1× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -1398.3%, a 1615.0% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -48.8%).

NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

NREF vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.1× larger
RNA
$12.5M
$11.1M
NREF
Growing faster (revenue YoY)
RNA
RNA
+482.9% gap
RNA
434.0%
-48.8%
NREF
Higher net margin
NREF
NREF
1615.0% more per $
NREF
216.6%
-1398.3%
RNA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
NREF
NREF
RNA
RNA
Revenue
$11.1M
$12.5M
Net Profit
$24.0M
$-174.4M
Gross Margin
Operating Margin
-1513.5%
Net Margin
216.6%
-1398.3%
Revenue YoY
-48.8%
434.0%
Net Profit YoY
58.7%
-117.0%
EPS (diluted)
$0.47
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NREF
NREF
RNA
RNA
Q4 25
$11.1M
Q3 25
$12.5M
$12.5M
Q2 25
$12.1M
$3.8M
Q1 25
$11.5M
$1.6M
Q4 24
$21.7M
$3.0M
Q3 24
$12.5M
$2.3M
Q2 24
$6.7M
$2.0M
Q1 24
$-12.8M
$3.5M
Net Profit
NREF
NREF
RNA
RNA
Q4 25
$24.0M
Q3 25
$50.9M
$-174.4M
Q2 25
$22.3M
$-157.3M
Q1 25
$26.0M
$-115.8M
Q4 24
$15.2M
$-102.3M
Q3 24
$23.3M
$-80.4M
Q2 24
$12.1M
$-70.8M
Q1 24
$-14.6M
$-68.9M
Operating Margin
NREF
NREF
RNA
RNA
Q4 25
Q3 25
-1513.5%
Q2 25
-4448.7%
Q1 25
-8360.9%
Q4 24
-4069.6%
Q3 24
-4200.9%
Q2 24
-4040.4%
Q1 24
-2178.6%
Net Margin
NREF
NREF
RNA
RNA
Q4 25
216.6%
Q3 25
407.0%
-1398.3%
Q2 25
184.5%
-4089.3%
Q1 25
225.6%
-7360.0%
Q4 24
69.9%
-3439.5%
Q3 24
186.4%
-3441.7%
Q2 24
179.7%
-3461.8%
Q1 24
114.3%
-1943.4%
EPS (diluted)
NREF
NREF
RNA
RNA
Q4 25
$0.47
Q3 25
$1.14
$-1.27
Q2 25
$0.54
$-1.21
Q1 25
$0.70
$-0.90
Q4 24
$0.71
$-0.80
Q3 24
$0.74
$-0.65
Q2 24
$0.40
$-0.65
Q1 24
$-0.83
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NREF
NREF
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$31.1M
$350.2M
Total DebtLower is stronger
$771.2M
Stockholders' EquityBook value
$388.0M
$1.9B
Total Assets
$5.3B
$2.1B
Debt / EquityLower = less leverage
1.99×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NREF
NREF
RNA
RNA
Q4 25
$31.1M
Q3 25
$17.9M
$350.2M
Q2 25
$9.1M
$243.9M
Q1 25
$19.2M
$254.2M
Q4 24
$3.9M
$219.9M
Q3 24
$34.7M
$370.2M
Q2 24
$4.3M
$575.8M
Q1 24
$13.5M
$471.4M
Total Debt
NREF
NREF
RNA
RNA
Q4 25
$771.2M
Q3 25
$720.9M
Q2 25
$815.6M
Q1 25
$831.5M
Q4 24
$799.3M
Q3 24
$815.5M
Q2 24
$861.0M
Q1 24
$843.3M
Stockholders' Equity
NREF
NREF
RNA
RNA
Q4 25
$388.0M
Q3 25
$375.4M
$1.9B
Q2 25
$348.2M
$1.2B
Q1 25
$343.7M
$1.3B
Q4 24
$336.5M
$1.4B
Q3 24
$335.8M
$1.5B
Q2 24
$327.5M
$1.2B
Q1 24
$327.1M
$830.9M
Total Assets
NREF
NREF
RNA
RNA
Q4 25
$5.3B
Q3 25
$5.3B
$2.1B
Q2 25
$5.4B
$1.4B
Q1 25
$5.4B
$1.5B
Q4 24
$5.4B
$1.6B
Q3 24
$5.7B
$1.6B
Q2 24
$6.6B
$1.3B
Q1 24
$7.1B
$951.5M
Debt / Equity
NREF
NREF
RNA
RNA
Q4 25
1.99×
Q3 25
1.92×
Q2 25
2.34×
Q1 25
2.42×
Q4 24
2.38×
Q3 24
2.43×
Q2 24
2.63×
Q1 24
2.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NREF
NREF
RNA
RNA
Operating Cash FlowLast quarter
$-4.5M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NREF
NREF
RNA
RNA
Q4 25
$-4.5M
Q3 25
$8.1M
$-156.2M
Q2 25
$3.3M
$-199.7M
Q1 25
$16.0M
$-124.8M
Q4 24
$4.4M
$-99.9M
Q3 24
$14.7M
$-65.6M
Q2 24
$-7.5M
$-65.0M
Q1 24
$17.7M
$-70.4M
Free Cash Flow
NREF
NREF
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
NREF
NREF
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
NREF
NREF
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
NREF
NREF
RNA
RNA
Q4 25
-0.19×
Q3 25
0.16×
Q2 25
0.15×
Q1 25
0.62×
Q4 24
0.29×
Q3 24
0.63×
Q2 24
-0.62×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons